Biofil Chemicals and Pharmaceuticals Limited (**BCPL**) is an established Indian pharmaceutical player specializing in the manufacturing, trading, and job work of pharmaceutical ingredients and chemical compounds. The company is currently executing a significant strategic pivot, transitioning from a multi-unit operational model to a consolidated, modernized manufacturing hub at its **Pithampur** facility. --- ### **Core Business Segments and Revenue Performance** BCPL operates through two primary divisions. While the Pharma division remains the bedrock of the company’s revenue, the Chemicals division has shown volatility due to market demand and operational shifts. | Segment | FY 2024-25 (INR Lacs) | FY 2023-24 (INR Lacs) | FY 2022-23 (INR Lacs) | | :--- | :--- | :--- | :--- | | **Pharma Division** | **2,666.03** | **2,786.79** | **2,419.61** | | **Chemicals Division** | **674.18** | **1,216.74** | **583.91** | | **Total Revenue** | **3,340.21** | **4,003.53** | **3,003.52** | **Key Financial Highlights:** * **Turnover Growth:** The company achieved a **34.49%** increase in turnover in **FY 2023-24** compared to the previous year. * **Profitability:** Net profit surged by **94.33%** to **₹90.13 Lacs** in **FY 2023-24**, driven by improved operational scale and strategic asset divestments. * **Quarterly Performance:** Profitability in the quarter ended **June 30, 2025**, was significantly bolstered by the disposal of the Sanwer Road undertaking. --- ### **Product Portfolio and Market Specialization** BCPL maintains a diverse portfolio ranging from basic iron salts to sophisticated steroids and hormones. * **Iron Salts & Excipients:** A major manufacturer of **Dried Ferrous Sulphate** (Crystal, Exsiccated, and Granular), **Microcrystalline Cellulose Powder (MCCP)**, and **Cellulose Powder (CP)**. * **Active Pharmaceutical Ingredients (APIs):** Core production includes **Diclofenac Sodium, Aceclofenac, Mefenamic Acid,** and **Fenbendazole**. * **High-Value Expansion (Steroids & Hormones):** The company has secured environmental clearances for **90 tons** of Steroids and Hormones, including **Dexamethasone IP, Dexamethasone Sodium Phosphate,** and **Betamethasone Sodium Phosphate**. * **Chemical Intermediates:** Proposed additions include **4-Nitro Benzyl Chloride, 3-Nitro Benzyl Chloride,** and **Paranitrobenzyl Alcohol**. --- ### **Strategic Restructuring and Asset Monetization** The company is currently unlocking capital from non-productive assets to fund regulatory upgrades and operational consolidation. **1. Disposal of Sanwer Road Unit (Indore):** In **February 2025**, members approved the sale of the Indore undertaking to consolidate operations at Pithampur. * **Plant & Machinery:** Sold to **Cyano Pharma Private Limited** for **₹2.15 Crores**. * **Land & Building:** Sold to **Formo Plast Private Limited** for **₹2.00 Crores**. **2. Pithampur Land Monetization:** BCPL occupies **1,06,875 sq. meters** at Pithampur, of which **94,463 sq. meters** has remained unutilized. The company is seeking to sell leasehold rights for **80,156 sq. meters** for a minimum consideration of **₹16.00 Crores**. **Planned Allocation of ₹16.00 Crores Proceeds:** * **₹5.50 Crores:** Renovation of the Pithampur unit to meet revised **Schedule M** and **Drug Policy** standards. * **₹4.00 Crores:** Settlement of long-standing dues and interest to **MPIDC** to resolve land disputes. * **₹4.75 Crores:** Working capital and capital expenditure. * **₹1.75 Crores:** General corporate purposes. --- ### **Operational Model and Strategic Partnerships** BCPL has shifted its business model to mitigate the loss of historical revenue streams and leverage synergistic relationships. * **Pivot from HLL Lifecare:** Historically, a tri-party agreement with **HLL Lifecare** provided steady income (avg. **₹153.24 Lacs** annually). Following regulatory suspensions at HLL in **November 2023**, this income dropped to zero. * **Synergy with Cyano Pharma Private Limited (CPPL):** BCPL has entered into a material related party transaction with **CPPL** valued at up to **₹35 Crores** for **FY 2024-25**. This allows BCPL to leverage CPPL’s established supply chain with state governments, optimizing marketing costs. * **Job Work:** The company continues to offer job work facilities for third-party pharmaceutical manufacturing. --- ### **Capital Structure and Liquidity Management** BCPL maintains a conservative, low-leverage financial profile, preferring internal accruals and asset sales over high-interest bank debt. | Component (INR in Lacs) | As at March 31, 2025 | As at March 31, 2024 | | :--- | :--- | :--- | | **Borrowings** | **47.13** | **43.89** | | **Cash and Cash Equivalents** | **25.53** | **228.35** | | **Adjusted Net Debt** | **21.60** | **(184.46)** | | **Total Equity** | **1,878.14** | **1,820.28** | * **Gearing Ratio:** The company remains highly under-leveraged. * **Inventory Policy:** Valued at the lower of cost or **Net Realisable Value (NRV)** using the **FIFO** method. * **Internal Controls:** Features defined authority levels and periodic audits by the Independent Audit Committee to ensure compliance with **Ind-AS** and **SEBI (LODR)** regulations. --- ### **Risk Factors and Mitigation Strategies** Investors should note the following challenges currently impacting the company: * **Regulatory Disruption:** Mandatory renovations to comply with revised **Schedule M** standards have caused partial manufacturing halts, leading to a decline in turnover as of **February 2026**. * **Financing Paradox:** The company’s **zero-debt status** has occasionally made it difficult to secure traditional bank loans for mandatory regulatory upgrades. * **Legal Encumbrances:** A writ petition from **2012** remains pending regarding the vacant land at Pithampur. * **Market & Commodity Risks:** BCPL is exposed to price volatility in raw materials like **sulphuric acid** and **iron waste**. * **Governance Gaps:** A temporary vacancy in the **Company Secretary** role (Dec 2024 – April 2025) resulted in a technical violation of SEBI regulations, though a new appointment was made effective **April 19, 2025**. --- ### **Leadership and Governance** * **Chairman & Managing Director:** **Mr. Ketan Shah** (Appointed effective **August 12, 2025**, for a 3-year term). * **Chief Financial Officer:** **Mr. Pavan Singh Rajput**. * **Company Secretary:** **Mr. Apoorv Jain**. * **Registered Office:** Relocated to **12/B Pologround, Indore**, effective **September 1, 2025**, to streamline administrative functions following the sale of the Sanwer Road site.